Brief Motivational Enhancement Therapy for Concurrent Disorders

This study is currently recruiting participants.
Verified August 2013 by Centre for Addiction and Mental Health
Sponsor:
Information provided by (Responsible Party):
Yarissa Herman, Centre for Addiction and Mental Health
ClinicalTrials.gov Identifier:
NCT01924039
First received: August 7, 2013
Last updated: March 20, 2014
Last verified: August 2013
  Purpose

The investigators are proposing a project that will examine the effectiveness of brief motivational enhancement therapy in a population with concurrent psychotic disorders and substance use disorders. This study will represent an emerging line of inquiry, as best practice interventions with this concurrent disordered (CD) populations are yet to be established.


Condition Intervention
Psychosis
Substance Use
Behavioral: Brief Motivational Enhancement Therapy
Other: treatment as usual

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Brief Motivational Enhancement Therapy for Individuals With Psychotic Disorders and Concurrent Substance Use Disorders

Resource links provided by NLM:


Further study details as provided by Centre for Addiction and Mental Health:

Primary Outcome Measures:
  • CD group attendance [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
    The primary outcome engagement with outpatient CD service as measured by CD group attendance.


Secondary Outcome Measures:
  • Alcohol Use Scale (AUS)/Drug Use Scale (DUS) [ Time Frame: 2 weeks and 3 months ] [ Designated as safety issue: No ]
    The secondary outcome is change in substance use as measured by the AUS and DUS


Other Outcome Measures:
  • Working Alliance Inventory [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
    A measure of alliance between the participant and the clinician conducting the MET sessions.


Estimated Enrollment: 30
Study Start Date: June 2013
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Brief Motivational Enhancement Therapy Behavioral: Brief Motivational Enhancement Therapy
The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
treatment as usual Behavioral: Brief Motivational Enhancement Therapy
The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
Other: treatment as usual
Treatment as usual includes case management as well as psychiatric appointments.

Detailed Description:

Motivational enhancement therapy (MET) is grounded in research that explores the process of change. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change.

The Two MET sessions adapted from Sampl and Kadden (2001) are prepared as two individual sessions to reflect the original design of MET, allowing for client's to be met at their respective stage of change. Further, individual sessions allow the treatment to be tailored to client's individual reasons for change and personal coping strategies. The use of the Personalized Feedback Report (PFR) further encourages treatment around client's personal concerns and goals (Ramchand et al., 2011; See appendix 1 for further detail).

In the first treatment session, the therapist provides feedback from the initial CD consultation, using the PFR to stimulate discussion about personal substance use and reasons for change. Rapport building is also a key element to the first session, during which a strong therapeutic alliance is initiated. The second session is aimed at strengthening the commitment to change, exploring goal setting, and preparation for group.

The Centre for Addiction and Mental Health (CAMH) Schizophrenia Division introduced a CD service in 2009. Since the time of its inception, more than 200 consultations have been conducted. Of those consultations, more than 80%recommended attending CD groups offered with the Schizophrenia Program. However, less than 10% have followed those recommendations and attended the CD group.

Based on what is known about challenges surrounding engagement of CD clients in recommended treatments coupled with guidelines for evidence-based treatment with this population (Ledgerwood et al., 2008; Tsuang et al., 2006; Roncero et al., 2011), the purpose of the current study is to explore the ability of MET to increase engagement in CD interventions for clients diagnosed with psychotic and substance use disorders.

  Eligibility

Ages Eligible for Study:   16 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Between the ages of 16-65
  • DSM-IV Diagnoses of a psychotic disorder and a substance use disorder (tobacco, alcohol and/or drug)
  • Fluent English speaker
  • Capable of giving written informed consent

Exclusion Criteria:

  • Any medical or neuropsychiatric condition, illness or disorder (e.g. unstable angina, severe dementia) that could compromise attendance to outpatient appointments.
  • Inability to provide informed consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01924039

Contacts
Contact: Yarissa Herman, D.Psych 4165358501 ext 6454 yarissa_herman@camh.net

Locations
Canada, Ontario
Centre for Addiction and Mental Health Recruiting
Toronto, Ontario, Canada, M5T 1R8
Contact: Yarissa Herman, D.Psych    416.535-8501 ext 6454    yarissa_herman@camh.net   
Sub-Investigator: Clairelaine Ouellet-Plamondon, M.D.         
Sub-Investigator: Tony George, M.D.         
Sponsors and Collaborators
Centre for Addiction and Mental Health
Investigators
Principal Investigator: Yarissa Herman, D.Psych Centre for Addiction and Mental Health
  More Information

No publications provided

Responsible Party: Yarissa Herman, Psychologist, Centre for Addiction and Mental Health
ClinicalTrials.gov Identifier: NCT01924039     History of Changes
Other Study ID Numbers: 055/2013
Study First Received: August 7, 2013
Last Updated: March 20, 2014
Health Authority: Canada: Ethics Review Committee

Keywords provided by Centre for Addiction and Mental Health:
Psychosis
Substance Use
Motivational Enhancement Therapy

Additional relevant MeSH terms:
Mental Disorders
Psychotic Disorders
Substance-Related Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on April 16, 2014